Role of nuclear factor κB in the central nervous system

Pharmacological Reports

Volumn 59, Issue 1, 2007, Pages 25-33

  Małek, Robert ^a   Borowicz, Kinga K ^a   Jargiełło, Małgorzata ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Neurodegeneration; Neuroprotection; NF B

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CELL ADHESION MOLECULE; COLONY STIMULATING FACTOR 1; CYCLOSPORIN A; CYTOKINE; DEFEROXAMINE; GLUCOCORTICOID; GREEN TEA EXTRACT; HERBIMYCIN A; I KAPPA B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN BETA LACTONE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYPHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME INHIBITOR; SALICYLATE SODIUM; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM FUNCTION; DEGENERATIVE DISEASE; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION; REVIEW;

EID: 34047092904     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 1996, 14, 649-683.
2. 2+ accumulation. Proc Natl Acad Sci USA, 1995, 92, 9328-9332.
3. Barger SW, Mattson MP: Induction of neuroprotective kappa B-dependent transcription by secreted forms of the Alzheimer's beta-amyloid precursor. Mol Brain Res, 1996, 40, 116-126.
4. Barkett M, Gilmore TD: Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene, 1999, 18, 6910-6924.
5. Bondeson J, Foxwell B, Brennan F, Feldmann, M: Defining therapeutic targets by using adenovirus: blocking NF ksppaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA, 1999, 96, 5668-5673.
6. Brand K, Eisele T, Kreusel U, Page M, Pap S, Haas M, Gerling A et al.: Dysregulation of monocytic nuclear factor kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol, 1997, 17, 1901-1909.
7. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M et al.: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest, 1996, 97, 1715-1722.
8. Castague V, Lefevre K, Clarke PGH: Dual role of the NF-kappaB transcription factor in the death of immature neurons. Neuroscience, 2001, 108, 517-526.
9. Clemens JA: Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants. Free Radic Biol Med, 2000, 28, 1526-1531.
10. Clemens JA, Stephenson DT, Yin T, Smalstig EB, Panetta JA, Little SP: Drug-induced neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor kappaB in rats. Stroke, 1998, 29, 677-682.
11. Crespel A, Coubes P, Rousset MC, Brana, C, Rougier A, Rondouin G, Bockaert J et al.: Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res, 2002, 952, 159-169.
12. Culmsee C, Garling N, Lehmann M, Nikolova-Karakashian M, Prehn JH, Mattson MP, Krieglstein J: Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurothrophin receptor P75. Neurosicience, 2002, 115, 1089-1108.
13. Digicaylioglu M, Lipton SA: Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature, 2001, 412, 641-647.
14. Da Van S, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T et al.: Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor. a proinflammatory pathway in Alzheimer's disease. Proc Natl Acad Sci USA, 1997, 94, 5296-5301.
15. Fridmacher V, Kaltshmidt B, Goudeau. B, Ndiaye D, Rossi FM, Pfeiffer J, Kaltschmidt C et al.: Forebrain-specific neuronal inhibition of nuclear factor kappaB activity leads to loss of neuroprotection. J Neurosci, 2003, 23, 9403-9408.
16. Grilli M, Memo M: Nuclear Factor-κB/Rel Proteins. A point of convergence of signalling pathways relevant in neuronal function and dysfunction. Biochem Pharmacol, 1999, 57, 1-7.
17. Grilli M, Pizzi M, Memo M, Spano P: Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science, 1996, 274, 1383-1385.
18. Guerrini L, Blasi F, Denis-Donini S: Synaptic activation of NF-κB by glutamate in cerebellar granule neurons in vitro. Proc Natl Acad Sci USA, 1995, 92, 9077-9081.
19. Guerrini L, Molteni A, Wirth T, Kistler B, Blasi F: Glutamate-dependent activation of NF-kappaB during mouse cerebellum development. J Neurosci, 1997, 17, 6057-6063.
20. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr: NF-kappaB controls Cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 1999, 19, 5785-5799.
21. Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J: Transcription factor NF-kappaB and inhibitor I kappsBalpha are localized in maccrophages in active multiple sclerosis lesion. J Neuropath Exp Neur, 1998, 57, 168-178.
22. Heck S, Lezoualc'h F, Engert S, Behl C: Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappaB. J Biol Chem, 1999, 274, 9828-9835.
23. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA et al.: Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA, 1997, 94, 7531-7536.
24. Irving EA, Hadingham SJ, Roberts J, Gibbons M, Chabot-Fletcher M, Roshak A, Parsons AA: Decreased nuclear factor-κB DNA binding activity following per manent focal cerebral ischaemia, in the rat. Neurosci Lett, 2000, 288, 45-48.
25. Janssen-Heininger YMW, Popter ME, Baeuerle PA: Recent advances towards understanding redox mechanisms in the activation of nuclear factor κB. Free Radio Biol Med, 2000, 28, 1317-1327.
26. Jung M, Zhang Y, Lee S, Dritschilo A: Correction of radiation sensitivity in ataxia telangiectasia, cells by a truncated I kappa B-alpha Science, 1995, 268, 1619-1621.
27. Kaltschmidt C, Kaltschmidt B, Baeuerle PA: Stimulation of ionotropic glutamate receptors activates transcription factor NF-κB in primary neurons. Proc Natl Acad Sci USA, 1995, 92, 9618-9622.
28. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H, Baeuerle PA: Constitutive NF-κB activity in neurons. Mol Cell Biol, 1994, 14, 3981-3992.
29. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C: Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis. Proc Natl Acad Sci USA, 1999, 96, 9409-9414.
30. Kassed CA, Butler TL, Navidomskis MT, Gordon MN, Morgan D, Pennypacker KR: Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-κB p50 in hippocampal neurons after injury. Mol Brain Res, 2003, 110, 152-157.
31. Kassed C, Willing A, Garbuzova-Davis S, Sanberg P, Pennypacker K: Lack of NF-κB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp Neurol, 2002, 176, 277-288.
32. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994, 265, 956-959.
33. Lerner-Natoli M, Montpied P, Rousset MC, Bockaert J, Rondouin G: Sequential expression of surface antigens and transcription factor NFkappaB by hippocampal cells in excitotoxicity and axperimental epilepsy. Epilepsy Res, 2000, 41, 141-154.
34. Levites Y, Youdim MBH, Maor G, Mandel S: Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol, 2002, 63, 21-29.
35. Mahon TM, O'Neill LA: Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-kappa B activation in T lymphocytes. Evidence for covalent modification of the p50 subunit. J Biol Chem, 1995, 270, 28557-29564.
36. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI et al.: Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum, 1996, 39, 583-591.
37. Mattson MP, Culmsee C, Yu ZF, Camandola S: Roles of nuclear factor κB in neuronal survival and plasticity. J Neurochem, 2000, 74, 443-456.
38. Meyer S, Kohler NG, Joly A: Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett, 1997, 413, 354-358.
39. Okuda H, Ogita K: Protective effiecft of N-methyl-D-aspartate against neuronal damages. (Japanese). Nihon Shinkei Seishin Yakurigaku Zasshi 2002, 22, 153-158.
40. O'Neill LA, Kaltschmidt C: NF-kappa B: A crucial transcription factor for glial and neuronal cell function. Trends Neurosci, 1997, 20, 252-258.
41. Pahl HL: Activators and target genes of Rel/NF-κB transcription factors. Oncogene, 1999, 18, 6853-6866.
42. Piccioli P, Porcile C, Stanzione S, Bisaglia M, Bajetto A, Bonavia R, Florio T et al.: Inhibition of nuclear factor-kappaB activation induces apoptosis in cerebellar granule cells. J Neurosci Res, 2001, 66, 1064-1073.
43. Porcile C, Piccioli P, Stanzione S, Bajetto A, Bonavia R, Barbero S, Florio T et al.: Proteasome inhibitors induce cerebellar granule cell death: inhibition of nuclear factor-κB activation. Ann NY Acad Sci, 2002, 973, 402-413.
44. Perkins ND: The Rel/NF-κB family friend and foe. Trends Biochem Sci, 2000, 434-440.
45. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC: Proteasome inhibitor PS519 rednoes infraction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke, 2000, 31, 1686-1693.
46. Ravati A. Ahlemeyer B, Becker A, Klumpp S, Krieglstein J: Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappaB. J Neurochem, 2001, 78, 909-919.
47. Ray A. Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA, 1994, 91, 752-756.
48. Rong Y, Baudry M: Seizure activity results in a rapid induction of nuclear factor-kappa B in adult but not juvenile rat limbic structures. J Neurochem, 1996, 67, 662-668.
49. Sappey C, Boelaert JR, Legrand-Poch S, Forceille C, Favier A, Piette J: Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retrov, 1995, 11, 1049-1061.
50. Shi X, Dong Z, Huang C, Ma W, Liu J, Ye J, Chan F et al.: The role of hydroxyl radical as a messenger in the activation of nuclear transcription factor NF-κB. Mol Cell Biochem, 1999, 194, 63-70.
51. Singh S, Aggarwal BB: Activation of transcription factor NF-kappa B is si suppressed by curcumin (diferulolymethane). J Biol Chem, 1995, 270, 24995-25000.
52. Stuhlmeier KM, Li H, Kao JJ: Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol, 1999, 57, 313-320.
53. Terai Y, Matsuo A, McGeer EG, McGeer PL: Enhancement of immunoreactivity for NF-kappa B in human cerebral infarctions. Brain Res, 1996, 739, 343-349.
54. Terai K, Matsuo A, McGeer PL: Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res, 1996, 735, 159-169.
55. Unlap T, Jope RS: Inhibition of NFκB DNA binding activity by glucocorticoids in rat brain. Neurosci Lett, 1995, 198, 41-44.
56. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 1998, 281, 1680-1683.
57. Wellmann H. Kaltschmidt B, Kaltschmidt C: Retrograde transport of transcription factor NF-kappa B in living neurons. J Biol Chem 2001, 276, 11821-11829.
58. Williams AJ, Hale SL, Moffett JR, Dave JR, Elliott PJ, Adams J, Tortella FC: Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via anti-inflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cerebr Blood Flow Metab, 2003, 23, 75-87.
59. Won SJ, Ko HW, Kim EY, Park EC, Huh K, Jung NP, Choi I et al.: Nuclear factor kappa B-mediated kainate neurotoxicity in the rat and hamster hippocampus. Neuroscience, 1999, 94, 83-91.
60. Vartiainen N, Goldsteins G, Keksa-Goldsteine V, Chan PH, Kastinaho J: Aspirin inhibits p44/42 mitogen-activated protein kinase and is protective against bypoxia/reoxygenation neuronal damage. Stroke, 2003, 34, 752-757.
61. Vartiainen N, Huang CY, Salminen A. Goldsteins G, Chan PH, Koistinaho J: Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclooxygenase inhibition. J Neurochem, 2001, 76, 480-489.
62. Xu L, Zhan Y, Wang Y, Feuerstein GZ, Wang X: Recombinant adenoviral expression of dominant negative IκBa protects brain from cebebral ischemic injury. Biochem Biopbys Res Commun, 2002, 299, 14-17.
63. Yu Z, Zhou D, Chang G, Mattson MP: Netuoprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. J Mol Neurosci 2000, 15, 31-44.